Global Prostate Cancer Market to 2021 - Market to rise at a moderate CAGR of 9.5% from $7.6bn in 2014 to $13.6bn in 2021

Dublin, April 18, 2016 -- Research and Markets has announced the addition of the "Prostate Cancer Market to 2021 - Increasing Disease Prevalence to be a Key Driver of Market Growth" report to their offering.

Prostate Cancer (PC) is a disease predominately of the elderly with 60% of cases diagnosed in men aged 65 or over. Prostate cancer is slow growing, and asymptomatic at its earliest stages. However, with the use of digital rectal examination, the PSA test, and the incidental discovery of tumors following resection of the prostate, the majority of PC cases are diagnosed at an early stage (60%).

As PC is slow growing, many patients can leave their disease untreated for extended periods of time with frequent monitoring (watchful waiting or active surveillance), with many patients dying from other causes before treatment is indicated. Surgery and/or radiotherapy is often curative when treatment is indicated for localized disease, with androgen deprivation being the standard of first-line care.

However, most patients ultimately develop resistant disease, for whom treatment options have historically been limited, with treatment with docetaxel being standard. The recent approval of Zytiga and Xtandi for docetaxel refractory disease in 2011 and 2012 have improved survival of resistant patients, but there is a clear clinical need to diversify the treatment options for this patient cohort.

The current late-stage drugs in development for PC address this clinical need, however, results so far have been mixed, with none demonstrating clinically transformative efficacy of safety. As a result, the growth in PC prevalence as a result of a global aging population is expected to be the key driver of this market throughout the forecast period.

Scope

- Global revenues for the PC market are forecast to rise at a moderate CAGR of 9.5% from $7.6bn in 2014 to $13.6bn in 2021.
- What factors are driving the market growth?
- How can the factors limiting growth be overcome in the future?
The pipeline addresses clinical need in the market; seven of the nine late-stage pipeline products are being developed as therapies for metastatic castration resistant disease.
- What other gaps in the market are being addressed by the current pipeline dynamics?
The variation in molecule type has shifted away from small molecules (predominately hormonal therapies), the dominance of which has decreased from 91% across marketed products to 50% across the pipeline.
- What are the dynamics of the remaining 50% of the pipeline?
- How does this reflect the need for novel targeted therapies?
There has been a significant shift away from hormonal therapies. Key mechanisms of action across the pipeline include cancer immunotherapies against PSMA, whole cell vaccines and targeted therapies against the PI3K/Akt/mTOR pathway.
- What is the scientific rationale behind these targets?
- How successful have drugs against these targets been? How successful are they expected to be in the future?
Several drugs are expected to be approved during the forecast period: ProstAtak, ODM201, ARN-509, and Tookad. However, their sales are expected to be limited by high costs and a lack of comparative trials.
- Where will these novel therapies fit into the current treatment algorithm for PC?

Companies Mentioned

- Aduro Biotech
- Algeta
- Alpharadin
- ARIAD Pharma
- Ascenta Therapeutics
- Astellas Pharma
- Bayer Schering
- Cell Genesys
- Janssen Biotech
- Oxford BioMedica
- Sanofi-Aventis
- Takeda Pharma

For more information visit http://www.researchandmarkets.com/research/cg73xb/prostate_cancer

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         [email protected]

         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900

         U.S. Fax: 646-607-1907
         Fax (outside U.S.): +353-1-481-1716

         Sector: Prostate Cancer Drugs